Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 60Neoplasms 41Carcinoma, Non-Small-Cell Lung 32Ovarian Neoplasms 27Neoplasm Metastasis 22Glioblastoma 19Lung Neoplasms 17Fallopian Tube Neoplasms 16Colonic Neoplasms 16Breast Neoplasms 16Rectal Neoplasms 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 13Carcinoma, Hepatocellular 12Stomach Neoplasms 10Glioma 10Carcinoma, Ovarian Epithelial 8Solid Cancers 7Sarcoma 7Melanoma 7Liver Neoplasms 7Brain Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumors 6Uterine Cervical Neoplasms 5Recurrence 5Lymphoma, Non-Hodgkin 5Astrocytoma 5Advanced Cancer 5Triple Negative Breast Neoplasms 4

Interventions

entinostat 2Gemcitabine 2pembrolizumab 1napabucasin 1interferon gamma-1b 1VB6-845 fusion protein 1Taxes 1Paclitaxel 1Oncolytic Virotherapy 1Nivolumab 1Leucovorin 1Irinotecan 1Interferon-gamma 1Immunotherapy 1Fluorouracil 1Cobicistat 1Cell Count 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Glandular and Epithelial × Bevacizumab × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡